Alterity Therapeutics Limited (PRNAF)
OTCMKTS · Delayed Price · Currency is USD
0.0070
+0.0040 (133.33%)
At close: Sep 23, 2025
Alterity Therapeutics Revenue
In the fiscal year ending June 30, 2025, Alterity Therapeutics had annual revenue of 5.44M AUD with 35.32% growth. Alterity Therapeutics had revenue of 3.83M in the half year ending June 30, 2025, with 150.44% growth.
Revenue
5.44M AUD
Revenue Growth
+35.32%
P/S Ratio
17.78
Revenue / Employee
604.32K AUD
Employees
9
Market Cap
63.39M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.44M | 1.42M | 35.32% |
| Jun 30, 2024 | 4.02M | 102.95K | 2.63% |
| Jun 30, 2023 | 3.92M | -1.21M | -23.56% |
| Jun 30, 2022 | 5.12M | 783.93K | 18.06% |
| Jun 30, 2021 | 4.34M | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
Alterity Therapeutics News
- 8 days ago - Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report - GlobeNewsWire
- 4 weeks ago - Alterity Therapeutics (ATHE) Unveils Promising Phase 2 Results for ATH434 in MSA - GuruFocus
- 4 weeks ago - Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders - GlobeNewsWire
- 5 weeks ago - Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders - GlobeNewsWire
- 7 weeks ago - Alterity Therapeutics (ATHE) Reports Promising Phase 2 Trial Results for ATH434 - GuruFocus
- 2 months ago - Alterity Therapeutics (ATHE) Secures A$20M in New Funding - GuruFocus
- 2 months ago - Alterity Therapeutics raises A$20 million in strategic placement - Seeking Alpha
- 2 months ago - Alterity Therapeutics Raises A$20.0 million in Strategic Placement - GlobeNewsWire